Emerging treatment for Tourette's disorder

Current Psychiatry Reports

Volumn 10, Issue 4, 2008, Pages 323-330

  Bloch, Michael H ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; BACLOFEN; BENZODIAZEPINE DERIVATIVE; BOTULINUM TOXIN; CLONAZEPAM; CLONIDINE; CLOZAPINE; ETIRACETAM; FINASTERIDE; FLUOXETINE; FLUPHENAZINE; FLUTAMIDE; GUANFACINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; ONDANSETRON; PERGOLIDE; PIMOZIDE; PLACEBO; QUETIAPINE; RISPERIDONE; SULPIRIDE; TALIPEXOLE; TETRABENAZINE; TIAPRIDE; TOPIRAMATE; UNINDEXED DRUG; ZIPRASIDONE; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT;

ADOLESCENCE; AKATHISIA; ATAXIA; BRAIN DEPTH STIMULATION; CARDIOTOXICITY; CHILDHOOD; CLINICAL TRIAL; DEPRESSION; DISABILITY; DIZZINESS; DRUG TOLERANCE; DYSPHORIA; DYSTONIA; EVIDENCE BASED PRACTICE; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; GILLES DE LA TOURETTE SYNDROME; HUMAN; HYPERPROLACTINEMIA; HYPOTENSION; INCREASED APPETITE; INSOMNIA; MENTAL DISEASE; METABOLIC DISORDER; MUSCLE WEAKNESS; NAUSEA; NEUROLOGIC DISEASE; ONSET AGE; PARKINSONISM; PERICARDIAL DISEASE; PLEURAL FIBROSIS; PSYCHOTHERAPY; QT PROLONGATION; RESTLESSNESS; REVIEW; SIDE EFFECT; SOMNOLENCE; SYMPTOM; TARDIVE DYSKINESIA; TIC; TRANSCRANIAL MAGNETIC STIMULATION; WEIGHT GAIN; XEROSTOMIA; DRUG THERAPY; ELECTROCONVULSIVE THERAPY; METHODOLOGY; OBSESSIVE COMPULSIVE DISORDER; PSYCHOLOGICAL ASPECT;

ADRENERGIC ALPHA-AGONISTS; ANTIPSYCHOTIC AGENTS; BOTULINUM TOXINS; DEEP BRAIN STIMULATION; DISABILITY EVALUATION; DRUG THERAPY; ELECTROCONVULSIVE THERAPY; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; TOURETTE SYNDROME; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 48749113310     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-008-0052-z     Document Type: Review

References (50)

1. Leckman JF, Grice DE, Barr LC, et al.: Tic-related vs. nontic-related obsessive compulsive disorder. Anxiety 1994, 1:208-215.
2. March JS, Franklin ME, Leonard H, et al.: Tics moderate treatment outcome with sertraline but not cognitive-behavior therapy in pediatric obsessive-compulsive disorder. Biol Psychiatry 2007, 61:344-347.
3. Bloch MH, Landeros-Weisenberger A, Kelmendi B, et al.: A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry 2006, 11: 622-632.
4. Scahill L, Erenberg G, Berlin CM Jr, et al.: Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx 2006, 3:192-206.
5. Sallee FR, Nesbitt L, Jackson C, et al.: Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder. Am J Psychiatry 1997, 154:1057-1062.
6. Ross MS, Moldofsky H: A comparison of pimozide and haloperidol in the treatment of Gilles de la Tourette's syndrome. Am J Psychiatry 1978, 135:585-587.
7. Shapiro E, Shapiro AK, Fulop G, et al.: Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome. Arch Gen Psychiatry 1989, 46:722-730.
8. Shapiro AK, Shapiro E: Controlled study of pimozide vs. placebo in Tourette's syndrome. J Am Acad Child Psychiatry 1984, 23:161-173.
9. Singer HS, Gammon K, Quaskey S: Haloperidol, fluphenazine and clonidine in Tourette syndrome: controversies in treatment. Pediatr Neurosci 1985, 12:71-74.
10. Goetz CG, Tanner CM, Klawans HL: Fluphenazine and multifocal tic disorders. Arch Neurol 1984, 41:271-272.
11. Atkins D, Best D, Briss PA, et al.: Grading quality of evidence and strength of recommendations. BMJ 2004, 328:1490.
12. Caine ED, Polinsky RJ, Kartzinel R, Ebert MH: The trial use of clozapine for abnormal involuntary movement disorders. Am J Psychiatry 1979, 136:317-320.
13. Scahill L, Leckman JF, Schultz RT, et al.: A placebo-controlled trial of risperidone in Tourette syndrome. Neurology 2003, 60:1130-1135.
14. Dion Y, Annable L, Sandor P, Chouinard G: Risperidone in the treatment of Tourette syndrome: a double-blind, placebo-controlled trial. J Clin Psychopharmacol 2002, 22:31-39.
15. Bruggeman R, van der Linden C, Buitelaar JK, et al.: Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study. J Clin Psychiatry 2001, 62:50-56.
16. Gaffney GR, Perry PJ, Lund BC, et al.: Risperidone versus clonidine in the treatment of children and adolescents with Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 2002, 41:330-336.
17. Sallee FR, Kurlan R, Goetz CG, et al.: Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry 2000, 39:292-299.
18. Budman CL, Gayer A, Lesser M, et al.: An open-label study of the treatment efficacy of olanzapine for Tourette's disorder. J Clin Psychiatry 2001, 62:290-294.
19. Stamenkovic M, Schindler SD, Aschauer HN, et al.: Effective open-label treatment of Tourette's disorder with olanzapine. Int Clin Psychopharmacol 2000, 15:23-28.
20. Mukaddes NM, Abali O: Quetiapine treatment of children and adolescents with Tourette's disorder. J Child Adolesc Psychopharmacol 2003, 13:295-299.
21. Kastrup A, Schlorter W, Plewnia C, Bartels M: Treatment of tics in Tourette syndrome with aripiprazole. J Clin Psychopharmacol 2005, 25:94-96.
22. Eggers C, Rothenberger A, Berghaus U: Clinical and neurobiological findings in children suffering from tic disease following treatment with tiapride. Eur Arch Psychiatry Neurol Sci 1988, 237:223-229.
23. Robertson MM, Schnieden V, Lees AJ: Management of Gilles de la Tourette syndrome using sulpiride. Clin Neuropharmacol 1990, 13:229-235.
24. Fountoulakis KN, Iacovides A, St Kaprinis G: Successful treatment of Tourette's disorder with amisulpride. Ann Pharmacother 2004, 38:901.
25. Tourette's Syndrome Study Group: Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 2002, 58:S27-S36.
26. Cummings DD, Singer HS, Krieger M, et al.: Neuropsychiatric effects of guanfacine in children with mild Tourette syndrome: a pilot study. Clin Neuropharmacol 2002, 25:325-332.
27. Scahill L, Chappell PB, Kim YS, et al.: A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 2001, 158:1067-1074.
28. Wilhelm S, Deckersbach T, Coffey Bj, et al.: Habit reversal versus supportive psychotherapy for Tourette's disorder: a randomized controlled trial. Am J Psychiatry 2003, 160:1175-1177.
29. Deckersbach T, Rauch S, Buhimann U, Wilhelm S: Habit reversal versus supportive psychotherapy in Tourette's disorder: a randomized controlled trial and predictors of treatment response. Behav Res Ther 2006, 44:1079-1090.
30. Himle MB, Woods DW, Piacentini JC, Walkup JT. Brief review of habit reversal training for Tourette syndrome. J Child Neurol 2006, 21:719-725.
31. Marras C, Andrews D, Sime E, Lang AE: Botulimun toxin for simple motor tics: a randomized, double-blind, controlled clinical trial. Neurology 2001, 56:605-610.
32. Porta M, Maggioni G, Ottaviani F, Schindler A: Treatment of phonic tics in patients with Tourette's syndrome using botutinum toxin type A. Neurol Sci 2004, 24:420-423.
33. Servello D, Porta M, Sassi M, et al.: Deep brain stimulation in 18 patients with severe Gilles de la Tourette syndrome refractory to treatment: the surgery and stimulation. J Neurol Neurosurg Psychiatry 2008, 79:136-142.
34. Maciunas RJ, Maddux BN, Riley DE, et at.: Prospective randomized double-blind trial of bilateral thalamic deep brain stimulation in adults with Tourette syndrome. J Neurosurg 2007, 107:1004-1014.
35. Mink JW, Walkup JT, Frey KA, et al.: Recommended guidelines for deep brain stimulations in Tourette syndrome. Mov Disord 2006, 21:1891-1898.
36. Mantovani A, Lisanby SH, Pieraccini F, et al.: Repetitive transcranial magnetic stimulation (sTMS) in the treatment of obsessive-compulsion disorder (OCD) and Tourette's syndrome (TS), Int J Neuropsychopharmacol 2006, 9:95-100.
37. Mantovani A, Leckman JF, Grantz H, et al.: Repetitive transcranial magnetic stimulation of the supplementary motor area in the treatment of Tourette syndrome: report of two cases. Clin Neurophysiol 2007, 118:2314-2315.
38. Karadenizli D, Dilbaz N, Bayam G: Gilles de la Tourette syndrome: response to electroconvulsive therapy. J ECT 2005, 21:246-248.
39. Rapoport M, Feder V, Sandor P: Response of major depression and Tourette's syndrome to ECT: a case report. Psychosom Med 1998, 60:528-529.
40. Strassnig M, Riedel M, Muller N: Electroconvulsive therapy in a patient with Tourette's syndrome and co-morbid obsessive compulsive disorder. World J Biol Psychiatry 2004, 5:164-166.
41. Trivedi HK, Mendelowitz AJ, Fink M: Gilles de la Tourette form of catatonia: response to ECT. J ECT 2003, 19:115-117.
42. Lipinski JF, Sallee FR, Jackson C, Sethuraman G: Dopamine agonist treatment of Tourette disorder in children: results of an open-label trial of pergolide. Mov Disord 1997, 12:402-407.
43. Gilbert DL, Sethuraman G, Sine L, et al.: Tourette's syndrome improvement with pergolide in a randomized, double-blind, crossover trial. Neurology 2000, 54:1310-1315.
44. Gilbert DL, Dure L, Sethuraman G, et al.: Tic reduction with pergolide in a randomized controlled trial in children. Neurology 2003, 60:606-611.
45. Jankovic J, Beach J: Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997, 48:358-362.
46. Jankovic J, Orman J: Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology 1988, 38:391-394.
47. Gonce M, Barbeau A: Seven cases of Gilles de la Tourette's syndrome: partial relief with clonazepam: a pilot study. Can J Neurol Sci 1977, 4:279-283.
48. Steingard RJ, Goldberg M, Lee D, DeMaso DR: Adjunctive clonazepam treatment of tic symptoms in children with comorbid tic disorders and ADHD. J Am Acad Child Adolesc Psychiatry 1994, 33:394-399.
49. Bortolato M, Muroni A, Marrosu F: Treatment of Tourette's syndrome with finasteride. Am J Psychiatry 2007, 164:1914-1915.
50. Abuzzahab FS, Brown VL: Control of Tourette's syndrome with topiramate. Am J Psychiatry 2001, 158:968.